-
The 1.2 billion yuan market for adjuvant hypotension treatment drugs welcomes competitors!
Time of Update: 2021-12-05
Jinyao Pharmaceutical is the second domestic company that has been evaluated, which means that this 1 billion yuan market has ushered in competitors .
The second company that passed the consistency evaluation of norepinephrine bitartrate injection .
-
The demand for high-end pharmaceutical equipment is growing stronger, and the market share is expected to continue to increase
Time of Update: 2021-12-05
From the above data, the market share of domestic high-end pharmaceutical equipment is continuing to increase, which also means that high-end equipment companies are ushering in opportunities and are expected to accelerate the pace of import substitution in the future .
-
500 million yuan of anti-gout drugs, two pharmaceutical companies have reviewed it in one day!
Time of Update: 2021-12-05
Prior to this, domestically produced febuxostat has been approved for listing, involving companies including Zhu Yangxin, Wanbang, and Hengrui.
The manufacturers involved include Jiangsu Wanbang (40mg, 16 tablets, winning price of 16.
-
6.5837 million yuan!
Time of Update: 2021-12-05
7 million yuan by the State Administration for Market Regulation for abusing its dominant position in the sales of Batroxobin concentrate in China; Enterprises have imposed administrative penalties for the implementation of monopoly agreements, with a total of 764 million yuan fined and confiscated .
-
Eli Lilly initiates first head-to-head study of CGRP migraine drug
Time of Update: 2021-12-05
Last weekend, Eli Lilly announced the initiation of a phase 4 clinical trial to compare its monthly subcutaneous CGRP migraine drug Emgality with oral tablets Nurtec ODT for the preventive treatment of paroxysmal migraine (EM) .
-
PARP inhibitor re-starts phase 0 clinical trials
Time of Update: 2021-12-05
AbbVie's PARP inhibitor Veliparib became the first drug to take a crab, and completed the first phase 0 clinical trial of a tumor drug.
-
Request for comments on the statistical guidelines for clinical research of rare disease drugs
Time of Update: 2021-12-05
Clinical research of rare disease drugs often faces problems such as difficulty in enrollment, long enrollment time, limited sample size, high heterogeneity of enrolled subjects, and lack of effective treatment methods, which require higher quality of clinical research .
-
The resignation of directors in the pharmaceutical industry, Zhendong Pharmaceutical also joins the ranks
Time of Update: 2021-12-05
Zhendong Pharmaceutical issued an announcement on the evening of November 19, stating that the company’s board of directors recently received a written application for resignation from director and president Ma Shifeng.
-
The domestic pharmaceutical R&D expenditure is expected to reach 49.6 billion US dollars in 2025, and the innovation environment will usher in a huge change
Time of Update: 2021-12-05
Nowadays, many companies have poured in and continue to promote drug innovation and research and development .
After years of hard work, China's biopharmaceutical industry has undergone significant changes, from the past generic drug-based pharmaceutical industry to innovative research and development.
-
Under the general trend of innovation, how should pharmaceutical companies break the bottleneck of transformation?
Time of Update: 2021-12-05
It is reported that the current leading traditional pharmaceutical companies such as CSPC, Kelun, and Chia Tai Tianqing are all planning to transform the research and development of innovative drugs and high-end generic drugs, and they are accelerating .
-
Centralized procurement will reshape the pharmaceutical industry, and these three giants will accelerate their "run"
Time of Update: 2021-12-04
Therefore, with the deepening of centralized procurement in the future, pharmaceutical companies with strong innovation or transformation capabilities, such as pharmaceutical companies with high A stock market value, Hengrui Pharmaceuticals, Mindray Medical, and WuXi AppTec, may accelerate their transformation and growth .
-
20 years of "marriage" finally broke up, Novartis sold 20.7 billion US dollars of Roche equity
Time of Update: 2021-12-04
Novartis will report the proceeds of the equity sale after the core adjustment, and the total proceeds are expected to be approximately US$14 billion .
-
Another 32 proprietary Chinese medicines in Shanxi have been withdrawn from the Internet!
Time of Update: 2021-12-04
On November 23, Shanxi Province Pharmaceutical Equipment Centralized Bidding Purchasing Network issued the "Notice on Announcement of Some Enterprises' Application for Revocation of Online Procurement Eligibility for Platforms" (hereinafter referred to as the "Notice"), and 32 Chinese patent medicines including Qingreling Granules will be removed from the Internet , Involving 8 pharmaceutical companies .
-
Dongguan City: allow supermarkets, 24-hour convenience stores and other places to operate Class B over-the-counter drugs
Time of Update: 2021-12-04
As long as the business area of drugs matches its scale, there is no problem with non-pharmacy companies selling drugs, so supermarkets, 24-hour convenience stores and other places The operation of Class B over-the-counter drugs is allowed .
-
Analysis of Antihypertensive Drugs Used in Shanghai Sample Hospitals
Time of Update: 2021-12-04
Top ten antihypertensive drugs commonly used in Shanghai sample hospitalsData source: China Pharmaceutical Industry Information Center Hospital Prescription Analysis System (RAS)The top four drugs with the most dosage are L-Amlodipine, Amlodipine, Valsartan, and Metoprolol.
-
Looking forward to 2022, which sub-tracks in the pharmaceutical and biological sector have great potential?
Time of Update: 2021-12-04
From the perspective of subdivisions, in the first three quarters of this year, the innovative drugs, medical devices, CXO and API sectors all showed rapid growth, while the revenue and net profit growth of the pharmaceutical retail sector declined slightly .
-
The centralized procurement of medical consumables continues to deepen, and the procurement of low-value consumables is blooming everywhere
Time of Update: 2021-12-04
Low-value medical consumables and test reagents are included in the scope of centralized procurement .
It is worth noting that as provinces and cities have successively started to purchase low-value consumables, the prices of related products have also dropped significantly.
-
Seeking future for domestic pharmaceutical equipment: technology and product manufacturing quality need to be improved
Time of Update: 2021-12-04
In recent years, it can also be seen that domestic pharmaceutical companies are starting to increase R&D investment and focus on personnel training, closely following the development trend of the biomedical industry and the application of new technologies, and continuously improve technological innovation capabilities and high-quality R&D.
-
Companies in the pharmaceutical industry continue to add and subtract, and actively embrace new changes in the market
Time of Update: 2021-12-04
For another example, on the evening of November 18, Kanghua Biological announced that the company reached a strategic cooperation and signed an agreement with Chengdu Xinran Bochuang Biotechnology Co.
-
Recently, the resignation wave of pharmaceutical company executives is still fierce!
Time of Update: 2021-12-04
Kanghong Pharmaceutical issued an announcement stating that ChenSU applied to resign from the company's directorship due to personal reasons, and at the same time resigned from the position of vice president.
